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Abstract 
Autosomal dominant spinocerebellar ataxias (SCAs) are a heterogeneous group 
of neurodegenerative disorders. In this study, we performed genetic analysis of a unique 
form of SCA (SCA36) that is accompanied by motor neuron involvement. 
Genome-wide linkage analysis and subsequent fine mapping for three unrelated 
Japanese families in a cohort of SCA cases, in whom molecular diagnosis had never 
been done, mapped the disease locus to the region of a 1.8 Mb stretch (LOD score of 
4.60) on 20p13 (D20S906– D20S193) harboring 37 genes with definitive open reading 
frames. We sequenced 33 of these and revealed a large expansion of an intronic 
GGCCTG hexanucleotide repeat in NOP56 and an unregistered missense variant 
(Phe265Leu) in C20orf194, but no mutations in PDYN and TGM6. The expansion 
showed complete segregation with the SCA phenotype in family studies, whereas 
Phe265Leu in C20orf194 did not. Screening the expansions in the SCA cohort cases 
revealed additional four occurrences, but none in the cohort of 27 Alzheimer’s cases, 
154 ALS cases, or 300 controls. Totally nine unrelated cases were found in 251 cohort 
SCA patients (3.6%). A founder haplotype was confirmed in these cases. RNA foci 
formation was detected in lymphoblastoid cells from affected subjects by fluorescence 
in situ hybridization. Double-staining and gel shift assay showed that (GGCCUG)n 
binds the RNA-binding protein SRSF2, but that (CUG)6 did not. In addition, 
transcription of MIR1292, a neighboring microRNA, was significantly decreased in 
lymphoblastoid cells of SCA patients. Our finding suggests that SCA36 is caused by 
hexanucleotide repeat expansions through RNA gain-of-function. 
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 Autosomal dominant spinocerebellar ataxias (SCAs) are a heterogeneous group 
of neurodegenerative disorders characterized by loss of balance, progressive gait, and 
limb ataxia
1-3
. We recently encountered two unrelated patients with intriguing clinical 
symptoms from a community in the Chugoku region in western mainland Japan
4
. These 
patients both showed complicated clinical features with ataxia as the first symptom, 
followed by characteristic late-onset involvement of the motor neuron system, with 
symptoms similar to amyotrophic lateral sclerosis (ALS[MIM 105400])
4
. Some SCAs 
(SCA1 [MIM 164400], SCA2 [MIM 183090], SCA3 [MIM 607047], and SCA6 [MIM 
183086]) are known to slightly affect motor neurons; however, their involvement is 
minimal and the patients usually do not develop skeletal muscle and tongue atrophies
4
. 
Of particular interest is that RNA foci have been recently demonstrated in hereditary 
disorders caused by microsatellite repeat expansions/insertions in the non-coding region 
of their responsible gene 
5-7
. The unique clinical features in these families have seldom 
been described in previous reports; therefore, we undertook a genetic analysis. 
A similar form of SCA was observed in five Japanese cases from a cohort of 251 
patients with SCA, in whom molecular diagnosis had not been performed, and who 
were followed by the Department of Neurology, Okayama University Hospital. These 
five cases originated from a city of 450,000 people in the Chugoku region. Thus, we 
suspected the presence of a founder mutation common to these five cases, prompting us 
to recruit these five families (Pedigrees 1–5) (Figure 1, Table 1). This study was 
approved by the Ethics Committee of Kyoto University and the Okayama University 
Institutional Review Board. Written informed consent was obtained from all subjects. 
An index of cases per family was investigated in some depth: IV-4 in Pedigree 1, II-1 in 
Pedigree 2, III-1 in Pedigree 3, II-1 in Pedigree 4, and II-1 in Pedigree 5. Mean age at 
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onset of cerebellar ataxia was 52.8 ± 4.3 years, and the disease was transmitted by an 
autosomal dominant mode of inheritance. All affected individuals started their ataxic 
symptoms, such as gait and truncal instability, ataxic dysarthria, and uncoordinated 
limbs, in their late forties to fifties. Magnetic resonance imaging revealed relatively 
confined and mild cerebellar atrophy (Figure 2A). Unlike previously known SCAs, all 
affected individuals with longer disease duration showed obvious signs of motor neuron 
involvement (Table 1). Characteristically, all affected individuals exhibited tongue 
atrophy with fasciculation to a greater or lesser extent (Figure 2B). Despite severe 
tongue atrophy in some cases, their swallowing function was relatively preserved, and 
they were allowed oral intake even at a later point after onset. In addition to tongue 
atrophy, skeletal muscle atrophy and fasciculation in the limbs and trunk appeared in 
advanced cases
4
. Tendon reflexes were generally mild-to-severely hyperreactive in most 
affected individuals, without severe lower limb spasticity and extensor plantar response. 
Electrophysiological studies were performed in an affected individual. Nerve 
conduction studies revealed normal findings in all the cases examined; however, an 
electromyogram showed neurogenic changes only in cases with skeletal muscle atrophy, 
indicating that lower motor neuropathy existed in this particular disease. Progression of 
motor neuron involvement in this SCA was typically and limited to the tongue and main 
proximal skeletal muscles in both upper and lower extremities, which is clearly different 
from typical ALS, which usually involves most skeletal muscles in a few years, leading 
to fatal results within several years. 
We conducted genome-wide linkage analysis for nine affected subjects and eight 
unaffected subjects in three informative families (Pedigrees 1–3; Figure 1). For 
genotyping, we used an ABI Prism Linkage Mapping Set (Version 2; Applied 
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Biosystems, Foster City, CA, USA) with 382 markers, 10 cM apart, for 22 autosomes. 
Fine-mapping markers (approximately 1 cM apart) were designed according to 
information from the uniSTS reference physical map in the NCBI database. A 
parametric linkage analysis was carried out using GENEHUNTER
8
, assuming an 
autosomal dominant model. The disease allele frequency was set at 0.000001 and a 
phenocopy frequency of 0.000001 was assumed. Population allele frequencies were 
assigned equal portions for individual alleles. We performed multipoint analyses for 
autosomes and obtained logarithm of the odds (LOD) scores. We considered LOD 
scores above 3.0 to be significant
8
. Genome-wide linkage analysis revealed a single 
locus on chromosome 20p13 with a LOD score of 3.20. Fine mapping increased the 
LOD score to 4.60 (Figure 3). Haplotype analysis revealed two recombination events in 
pedigree 3, delimiting a1.8-Mb region (D20S906– D20S193) (Figure 1). We further 
tested whether the five cases shared the haplotype. As shown in Figure 1, pedigrees 4 
and 5 were confirmed to have the same haplotype as pedigrees 1, 2, and 3, indicating 
that the 1.8 Mb region is very likely to be derived from a common ancestor. 
The 1.8-Mb region harbors 44 genes (NCBI, Build 37.1). We eliminated two 
pseudogenes and five genes (LOC441938, LOC100289473, LOC100288797, 
LOC100289507 and LOC100289538) from the candidates. Evidence view showed that 
the first, fourth, and fifth genes were not found in the contig in this region, while the 
second and third of these genes had mismatches over the mouse genes. Sequence 
similarities among paralogue genes defied direct sequencing of four genes: SIRPD 
[NM 178460.2], SIRPB1 [NM 603889], SIRPG [NM 605466], and SIRPA [NM 
602461]. Thus, we sequenced 33 of 37 genes (PDYN [MIM 131340], STK35 [MIM 
609370], TGM3 [MIM 600238], TGM6 [NM_198994.2], SNRPB [MIM 182282], 
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SNORD119 [NR_003684.1], ZNF343 [NM_024325.4], TMC2 [MIM 606707], NOP56 
[NM_006392.2], MIR1292 [NR_031699.1], SNORD110 [NR_003078.1], SNORA51 
[NR_002981.1], SNORD86 [NR_004399.1], SNORD56 [NR_002739.1], SNORD57 
[NR_002738.1], IDH3B [MIM 604526], EBF4 [MIM 609935], CPXM1 
[NM_019609.4], C20orf141 [NM_080739.2], FAM113A [NM_022760.3], VPS16 
[MIM 608550], PTPRA [MIM 176884], GNRH2 [MIM 602352], MRPS26 [MIM 
611988], OXT [MIM 167050], AVP [MIM 192340], UBOX5 [NM_014948.2], 
FASTKD5 [NM_021826.4], ProSAPiP1 [MIM 610484], DDRGK1 [NM_023935.1], 
ITPA [MIM 147520], SLC4A11 [MIM 610206], and C20orf194 [NM_001009984.1] ) 
(Figure 2C). All noncoding and coding exons, and the 100 bp up- and down-stream of 
the splice junctions of these genes were sequenced in two index cases (IV-4 in 
pedigree1 and III-1 in pedigree 3) and in three additional cases (II-1 in pedigree 2, II-1 
in pedigree 4 and II-1 in pedigree 5) using specific primers (Supplemental Table 1). 
Eight unregistered variants were found among the two index cases. Among these, there 
was a coding variant (Phe265Leu), g.3324373 C > G of C20orf194, while the other 
seven included one synonymous variant (Leu565Leu in ZNF343; g.2463912 T>A) and 
six non-splice-site intronic variants (supplemental Table 2). We tested segregation by 
sequencing exon 11 of C20orf194 in IV-2 and III-5 in the pedigree 1. Neither IV-2 nor 
III-5 had this variant. We thus eliminated C20orf194 as a candidate. Missense 
mutations in PDYN and TGM6, which have been recently reported as causes of SCA, 
mapped to 20p12.3-p13
9; 10
, but none were detected in the five index cases studied here 
(Supplemental Table 2).  
Possible expansions of repetitive sequences in these 33 genes were investigated 
when intragenic repeats were indicated in the database (UCSC Genome 
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Bioinformatics). Expansions of the hexanucleotide repeat GGCCTG (rs68063608) 
were found in intron 1 of NOP56 (Figure 2D) in all five index cases, using a 
repeat-primed PCR method
11-13
. An outline of the repeat-primed PCR experiment is 
described in Figure 2D. Briefly, the fluorescent dye-conjugated forward primer 
corresponded to the region upstream of the repeat of interest. The first reverse primer 
consisted of four units of the repeat (GGCCTG) and a 5′-tail used as an anchor. The 
second reverse primer was an “anchor” primer. These primers are described in 
Supplemental Table 3. Complete segregation of the expanded hexanucleotide was 
confirmed in all pedigrees, and the maximum repeat size in nine unaffected members 
was eight (data not shown).  
In addition to the SCA cases in five pedigrees, four unrelated cases 
(SCA#1–SCA#4) were found to have a (GGCCTG)n allele by screening in the cohort 
SCA patients (Table 1). Neurological examination was reevaluated in these four cases, 
revealing both ataxia and motor neuron dysfunction with tongue atrophy and 
fasciculation (Table 1). Totally nine unrelated cases were found in the 251 cohort 
patients with SCA (3.6%). To confirm the repeat expansions, Southern blot analysis 
was conducted in six affected subjects (Ped2_II-1, Ped3_III-1, Ped3_III-2, Ped5_I-1, 
Ped5_II-1 and SCA#1). The data showed >10 kb of repeat expansions in the 
lymphoblastoid cell lines (LCLs) obtained from the SCA patients (Figure 2E). 
Furthermore, the numbers of GGCCTG repeat expansion were estimated by Southern 
blotting in other 11 cases. The expansion analysis revealed approximately 1500 to 
2500 in 17 cases (Table 1). There was no negative association between age of onset 
and the number of GGCCTG repeats (n=17, r=0.42, p=0.09; Supplemental Figure 1), 
and no obvious anticipation in the current pedigrees. 
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To investigate the disease specificity and disease spectrum of the hexanucleotide 
repeat expansions, we tested the repeat expansions in an Alzheimer's disease [MIM 
104300] cohort and an ALS cohort followed up by the Department of Neurology, 
Okayama University Hospital. We also recruited Japanese controls, who were 
confirmed to be free from brain lesions by magnetic resonance imaging and magnetic 
resonance angiography, as described previously
14
. Screening of the 27 Alzheimer's 
disease cases and 154 ALS cases failed to detect further cases with repeat expansions. 
The GGCCTG repeat sizes ranged from three to eight in 300 Japanese controls (5.9 ± 
0.8 repeats), suggesting that the >10-kb repeat expansions were mutations.  
Expression of Nop56, an essential component of the splicing machinery
15
, was 
examined by RT-PCR using primers for wild-type mouse Nop56 cDNA (Supplemental 
Table 3). Expression of Nop56 mRNA was detected in various tissues including central 
nervous system, while a very weak signal was detected in spinal cord (Figure 4A). 
Immunohistochemistry using an anti-mouse Nop56 antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) detected the Nop56 protein in Purkinje cells of the cerebellum as 
well as motor neurons of the hypoglossal nucleus and the spinal cord anterior horn 
(Figure 4B), suggesting that these cells may be responsible for tongue and muscle 
atrophy in the trunk and limbs, respectively. Western blotting also confirmed the 
presence of the Nop56 protein in neural tissues (Figure 4C), where Nop56 is localized 
in both the nucleus and cytoplasm.  
Alterations of NOP56 RNA expression and protein levels in LCLs from patients 
were examined by real-time RT-PCR and western blotting. The primers for quantitative 
PCR of human NOP56 cDNA are described in Supplemental Table 3. Immunoblotting 
was performed using an anti-human NOP56 antibody (Santa Cruz Biotechnology, Santa 
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Cruz, CA, USA). We found no decrease in NOP56 RNA expression or protein levels in 
LCLs from these patients (Figure 5A). To investigate abnormal splicing variants of 
NOP56, we performed RT-PCR using the primers covering the region from the 5’ UTR 
to exon 4 around the repeat expansion (Supplemental Table 3); however, no splicing 
variant was observed in LCLs from the cases (Figure 5B). Furthermore, 
immunocytochemistry for NOP56 and coilin, a marker of the Cajal body, where NOP56 
functions
16
, was carried out. NOP56 and coilin distributions were not altered in LCLs of 
the SCA patients (Figure 5C), suggesting that qualitative or quantitative changes in the 
Cajal body did not occur. These results indicated that haploinsufficiency could not 
explain the observed phenotype. 
We performed fluorescent in situ hybridization to detect RNA foci containing the 
repeat transcripts in LCLs from patients, as previously described
17; 18
. Lymphoblastoid 
cells from two SCA patients (Ped2_II-2 and Ped5_I-1) and two control subjects were 
analyzed. An average of 2.1 ± 0.5 RNA foci/cell were detected in 57.0% of LCLs (n = 
100) from the SCA subjects using a nuclear probe targeting the GGCCUG repeat, 
whereas no RNA foci were observed in control LCLs (n = 100) (Figure 6A). In contrast, 
a probe for the CGCCUG repeat, another repeat sequence in intron 1 of NOP56, 
detected no RNA foci in either SCA or control LCLs (n = 100 each) (Figure 6A) 
indicating that the GGCCUG repeat was specifically expanded in the SCA subjects. The 
specificity of the RNA foci was confirmed by sensitivity to RNase A treatment and 
resistance to DNase treatment (Figure 6A). 
Several reports have suggested that RNA foci play a role in the etiology of SCA 
through sequestration of specific RNA-binding proteins
5-7
. In silico searches (ESEfinder 
3.0) predicted an RNA-binding protein, SRSF2 [MIM 600813], as a strong candidate 
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for binding the GGCCUG repeat. Double-staining with the probe for the GGCCUG 
repeat and an anti-SRSF2 antibody (Sigma-Aldrich Inc., Tokyo, Japan) was performed. 
The results showed co-localization of RNA foci with SRSF2, while NOP56 and coilin 
were not co-localized with the RNA foci (Figure 6B), suggesting a specific interaction 
of endogenous SRSF2 with the RNA foci in vivo.  
To further confirm the interaction, gel-shift assays were carried out to investigate 
the binding activity of SRSF2 with (GGCCUG)n. Synthetic RNA oligonucleotides (200 
pmol), (GGCCUG)4 or (CUG)6 , which is the latter part of the hexanucleotide, as well as 
the repeat RNA involved in myotonic dystrophy type 1 (DM1) [MIM 160900]18 and 
SCA8 [MIM 608768]
5
,were denatured and immediately mixed with different amounts 
(0, 0.2, or 0.6 μg) of recombinant full-length human SRSF2 protein (Abcam, Cambridge, 
UK). The mixtures were incubated and the protein-bound probes were separated from 
the free forms by electrophoresis on 5–20% native polyacrylamide gels. The separated 
RNA probes were detected with SYBR Gold staining (Invitrogen, Carlsbad, CA, USA). 
We found a strong association of (GGCCUG)4 with SRSF2 in vitro in comparison to 
(CUG)6 (Figure 6C). Collectively, we concluded that (GGCCUG)n interacts with 
SRSF2. 
 It is notable that MIR1292 is located just 19 bp 3’ of the GGCCTG repeat 
(Figure 2D). MicroRNAs such as MIR1292 are small non-coding RNAs that regulate 
gene expression by inhibiting translation of specific target mRNAs
19; 20
. MicroRNAs are 
believed to play important roles in key molecular pathways by fine-tuning gene 
expression
19; 20
. Recent studies have revealed that microRNAs influence neuronal 
survival and are also associated with neurodegenerative diseases
21; 22
. In silico searches 
(Target Scan Human 5.1) predicted glutamate receptors (GRIN2B [MIM 138252] and 
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GRIK3 [MIM 138243]) as potential target genes. Real time RT-PCR using TaqMan 
probes for miRNA (Invitrogen, Carlsbad, CA, USA) revealed that the levels of both 
mature and precursor MIR1292 were significantly decreased in SCA LCLs (Figure 6D), 
indicating that the GGCCTG repeat expansion decreased the transcription of MIR1292. 
A decrease in MIR1292 expression may upregulate glutamate receptors in particular cell 
types, e.g. GRIK3 in stellate cells in the cerebellum
23
, leading to ataxia because of 
perturbation of signal transduction to the Purkinje cells. In addition, it has been 
suggested, based on ALS mouse models
24; 25
, that excitotoxicity mediated by a type of 
glutamate receptor, the NMDA receptor including GRIN2B, is involved in loss of spinal 
neurons. A very slowly progressing and mild form of the motor neuron disease, i.e., 
mostly limited to fasciculation of tongue, limbs and trunk, may also be compatible with 
such a functional dysregulation rather than degeneration 
In the present study, we have conducted genetic analysis to find a genetic cause 
for the unique SCA with motor neuron disease. With extensive sequencing the 1.8 MB 
linked region, we found a large hexanucleotide repeat expansions in NOP56, which 
were completely segregated with SCA in five pedigrees and was found in four unrelated 
cases with the similar phenotype. The expansion was neither found in 300 controls or 
other neurodegenerative diseases. We further proved that repeat expansions of NOP56 
induce RNA foci and sequester SRSF2. Taken together, we thus concluded that 
hexanucleotide repeat expansions are considered to cause SCA by a toxic RNA 
gain-of-function mechanism and name this unique SCA as SCA36. Haplotype analysis 
indicates that hexanucleotide expansions are derived from a common ancestor. The 
prevalence of the SCA36 was estimate 3.6% in the SCA cohort in Chugoku district, 
suggesting that prevalence of SCA36 may be geographically limited to the western part 
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of Japan and is rare even in Japanese SCAs.  
Expansion of tandem nucleotide repeats in different regions of respective genes 
(most often the triplets CAG and CTG) has been shown to cause a number of inherited 
diseases over the past decades. An expansion in the coding region of a gene causes a 
gain of toxic function and/or reduces the normal function of the corresponding protein 
at the protein level. RNA-mediated noncoding repeat expansions have been also been 
identified to cause eight other neuromuscular disorders, namely DM1, DM2 [MIM 
602668], fragile X tremor/ataxia syndrome (FXTAS) [MIM 300623], Huntington’s 
disease-like 2 (HDL2) [MIM 606438], SCA8, SCA10 [MIM 603516], SCA12 [MIM 
604326], and SCA31 [MIM 117210] 
26
. The repeat numbers in affected alleles of 
SCA36 are among the largest seen in this group of diseases (i.e. thousands of repeats). 
Moreover, SCA36 is not merely a non-triplet repeat expansion disorder after SCA10, 
DM2, and SCA31, but is now proven to be a human disease caused by a large 
hexanucleotide repeat expansion. In addition, no or only weak anticipation has been 
reported for non-coding repeat expansion in SCA, while clear anticipation has been 
reported for most polyglutamine expansions in SCA
2
. As such, absence of anticipation 
in SCA36 is in accord with previous studies on SCAs with noncoding repeat expansions. 
The common hallmark in these noncoding repeat expansion disorders is transcribed 
repeat nuclear accumulations with respective repeat RNA-binding proteins, which are 
considered to primarily trigger and develop the disease at the RNA level. However, 
multiple different mechanisms are likely to be involved in each disorder. There are at 
least two possibilities to explain motor neuron involvement of SCA 36: gene and tissue 
specific splicing specificity of SRSF2 and involvement of microRNA. In SCA36, there 
is the possibility that the adverse effect of the expansion mutation is mediated by 
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downregulation of microRNA expression. The biochemical implication of microRNA 
involvement cannot be evaluated in this study, because availability of tissue samples 
from affected cases was limited to LCLs. Given definitive downregulation of 
microRNA 1291 in LCLs, we should await further study to substantiate its involvement 
in affected tissues. Elucidating which mechanism(s) play a critical role in the 
pathogenesis will be required to determine whether cerebellar degeneration and motor 
neuron disease occur with a similar scenario. 
In conclusion, expansion of the intronic GGCCTG hexanucleotide repeat in 
NOP56 causes a unique form SCA (SCA36), which shows not only ataxia, but also 
motor neuron dysfunction. This characteristic disease phenotype can be explained by 
the combination of RNA gain-of-function and MIR1292 suppression. Further studies are 
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Figure 1. Pedigree Charts of the Five SCA Families (Pedigrees 1–5) 
Haplotypes are shown for nine markers from D20S906 (1,505,576 bp) to D20S193 
(3,313,494 bp), spanning 1.8 Mb on chromosome 20p13. NOP56 is located at 
2,633,254–2,639,039 bp (Build 37.1). Filled and unfilled symbols indicate affected and 
unaffected individuals, respectively. Squares and circles represent males and females, 
respectively. A slash indicates a deceased individual. The putative founder haplotypes 
among patients are shown in boxes constructed by GENHUNTER
8
. Arrows indicate the 
index case. The pedigrees were slightly modified for privacy protection. 
 
Figure 2. Motor Neuron Involvement and (GGCCTG)n Expansion in the First 
Intron of NOP56  
(A) Magnetic resonance imaging of an affected subject (SCA#3) showed mild 
cerebellar atrophy (arrow), but no other cerebral or brainstem pathology.  (B) Tongue 
atrophy (arrow) was observed in SCA#1. (C) Physical map of the 1.8-Mb linkage region 
from D20S906 (1,505,576 bp)–D20S193 (3,313,494 bp), with 33 candidate genes 
shown, as well as the direction of transcription (arrows). (D) The upper portion of the 
panel shows the scheme of primer binding for repeat-primer PCR analysis. In the lower 
portion, sequence traces of the PCR reactions are shown. Red lines indicate the size 
markers. The vertical axis indicates arbitrary intensity levels. A typical saw tooth pattern 
is observed in an affected pedigree. (E) Southern blotting of lymphoblastoid cell lines 
(LCLs) from SCA cases and three controls. Genomic DNA (10 g) was extracted from 
Epstein-Barr virus immortalized LCLs derived from six affected subjects (Ped2_II-1, 
Ped3_III-1, Ped3_III-2, Ped5_I-1, Ped5_II-1 and SCA#1) and digested with 2 units of 
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AvrII overnight (New England Biolabs Inc., Beverly, MA, USA). A probe covering exon 
4 of NOP56 (452 bp) was PCR amplified from human genomic DNA using primers 




Figure 3. Multipoint Linkage Analysis with 10 Markers on Chromosome 20p13. 
 
Figure 4. Nop56 in Mouse Nervous System 
(A) RT-PCR analysis of Nop56 (422 bp) in various mouse tissues. cDNA (25 ng) 
collected from various organs of C57BL/6 mice were purchased from GenoStaf (Tokyo, 
Japan).  (B) Immunohistochemical analysis of Nop56 in cerebellum, hypoglossal 
nucleus, and spinal cord anterior horn in a wild male Slc:ICR mice at 8 weeks of age 
(Japan SLC Inc., Shizuoka, Japan). The arrows indicate anti- Nop56 antibody staining. 
The negative control was the cerebellar sample without the Nop56 antibody treatment. 
Bar, 100 µm (C) Western blotting of Nop56 protein (66 kDa) in cerebellum and 
cerebrum. Protein sample (10 µg) was subjected to immunoblotting. LaminB1, a 
nuclear protein, and beta-tubulin, were used as loading controls. 
 
Figure 5. Analysis of NOP56 in LCLs from SCA patients. 
(A) mRNA expression (upper panel) and protein levels (lower panel) in LCLs from 
cases (n = 6) and controls (n = 3) were measured by RT-PCR and western blotting, 
respectively. cDNA (10 ng) was transcribed from total RNA isolated from LCLs and 
used for RT-PCR. Western blotting was performed using protein sample (40 µg) 
extracted from LCLs. The data indicate the mean ± SD relative to the levels of PP1A 
and GAPDH, respectively. There was no significant difference between LCLs from 
 19 
controls and cases. (B) Analysis for splicing variants of NOP56 cDNA. RT-PCR with 10 
ng cDNA and primers corresponding to the region from 5’ UTR to exon 4 around the 
repeat expansion were performed. The PCR product has an expected size of 230 bp. (C) 
Immnunocytochemistry for NOP56 and coilin. Green signals represent NOP56 or coilin. 
Shown are representative samples from 100 observations of controls or cases. 
 
Figure 6. RNA Foci Formation and Decreased Transcription of MIR1292 
(A) Cells were fixed on coverslips and then hybridized with solutions containing either 
a Cy3-labeled C(CAGGCC)2CAG or G(CAGGCG)2CAG oligonucleotide probe (1 
ng/μl). For controls, the cells were treated with 1000 U/ml DNase or 100 g/ml RNase 
for 1 h at 37°C prior to hybridization, as indicated. After a wash step, coverslips were 
placed on the slides in the presence of ProLong Gold with DAPI mounting media 
(Molecular Probes, Tokyo, Japan), and photographed with a fluorescence microscope. 
The upper panels indicate LCLs from an SCA case and a control hybridized with 
C(CAGGCC)2CAG (left) or G(CAGGCG)2CAG (right). Red and blue signals represent 
RNA foci and the nucleus (DAPI staining), respectively. Similar RNA foci formation 
was confirmed in LCLs from another index case. The lower panels show RNA foci in 
SCA LCLs treated with DNAse or RNAse. (B) Double-staining was performed with the 
probe for (GGCCUG)n (red) and anti-SRSF2, NOP56, or coilin antibody (green). (C) 
Gel-shift assays revealed specific binding of SRSF2 to (GGCCUG)4 but little t to 
(CUG)6 . (D) RNA samples (10 ng) were extracted from LCLs of controls (n = 3) and 
cases (n = 6). MicroRNAs were measured using a TaqMan probe for precursor (Pri-) 
and mature MIR1292. The data indicate the mean ± SD, relative to the levels of PP1A or 
RNU6. *: P < 0.05. 
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Table 1. Clinical characteristics of affected subjects            
Pedigree 
No. 
Patient ID Gender Onset age (y) Current age (y) Ataxia 








Genotype of GGCCTG 
repeats 
1 
III-5 M 50 70 +++ N.D. N.D. N.D. g.263397_263402[6]+(1800)  
III-6 F 52 68 ++ + + + g.263397_263402[6]+(2300)  
IV-2 F 57 63 + - - + g.263397_263402[6]+(2300) 
IV-4 M 50 59 + - - + g.263397_263402[6]+(2300) 
2 
II-1 M 55 77 +++ ++ + + g.263397_263402[6]+(2200) 
II-2 F 53 70 ++ N.D. N.D. N.D. g.263397_263402[6]+(2200)  
3 
II-3 M 58 77 ++ ++ + + g.263397_263402[3]+(2300)  
III-1 M 56 62 + - - ± g.263397_263402[8]+(2200) 
III-2 M 51 61 ++ + + + g.263397_263402[6]+(1800) 
4 
I-1 M 57 died in 2001 at 83 ++ N.D. N.D. N.D. g.263397_263402[5]+(1800) 
II-1 F 48 61 ++ + ± ++ g.263397_263402[6]+(2000) 
5 
I-1 M 57 86 ++ +++ + + g.263397_263402[5]+(2000) 
II-1 F 47 58 ++ + + + g.263397_263402[8]+(1700)  
  SCA#1 M 52 69 +++ +++ +++ +++ g.263397_263402[5]+(2200)  
  SCA#2 F 43 53 +++ - - + g.263397_263402[6]+(1800) 
  SCA#3 M 55 60 ++ - - ++ g.263397_263402[8]+(1700) 
 SCA#4 M 57 81 +++ + + +++ g.263397_263402[5]+(2200) 
Mean   52.8        
SD   4.3        






















































































































































































































































































































































































































Expansion of Intronic GGCCTG Hexanucleotide Repeat in NOP56 Causes a Type 
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Supplemental Text and Figures
  
Supplemental Figure 1. Correlation of the Number of Repeats with Age of Onset.  
A scatter plot shows no negative correlation between GGCCTG repeat number and 
onset age (n=17, r=0.42, p=0.09).  
 
Supplemental Table 1. Primers used for amplification of candidate genes (Human build 37.1) 
 PDYN exon 3 CTTTGGGCCTCTGCTTTACCT TCCAGGCCATCTATAGGGCAexon 4 TCCCCTACCTTTATGCACCA AACATACTCCCACGCAGAAGA
STK35 exon 1 CGGATCACGGGAATTTCG ATTGGCTGAAAAGTTCGGCT
exon 2 TGGCTTCCGTCTTAAAGGG CAGGAAAGGAGGGTGTGTCA
exon 3 GTCCCCTTGGAGCAGTTGTTT AATCACTTGAACTCGGGAGGT
exon 5 TCTCTTTAGAGCTCTGCCCCA TTGCCCACATTGAATTTCTT
TGM3 exon 1 TTATTATCTGCCCCCTTCTCC CTCTGGCTAGCACCCTAAAAT
exon 3 AACAGGATGCACAGAGGTTCA TCCCTCTTGATTTGAGGATGG
exon 4 TGGCCTGTATGTTTGTTCCA TTGGGGCTTGGAGAGATAGAA
exon 5 TCAGGGGAGGGCTAAAGGT AGGTGGCCAATGAAAGTCTT
exon 6 TTCCTGTGGTTCTTGCCAGT TGTAAAGAGTGTGCGTGCCTA
exon 7,8 TTCAATCATGGCCTTTGGCT AATCAGCATTGCCAGCAGTT
exon 9 TGTTGTCATGCTGCACTGTTG TTGTTTTAATCCCATCATGCA
exon 10 GGTTGCAGTGGTCCTGGAA GCAATCCTATCATTCAGGCA
exon 11 TGAAAGTCGAATGCCTGCTA TCCAAAGCATTAATACATGGC
exon 12 AGATCCTCCCACCAGCTCA AAAACTCTCCTTTGCCCTCTG
exon 13 TCTCCCCTTCTTCATCCTCA CCAAACCAAATGCAAAAGCAG
exon 14 CTCCATCAGAACAGGACAGGA CACTCCCTTTGGACATTGAA
TGM6 exon 1 TGATTTTGTGTCTCGTGGGTG AGTTCATGTGTTCATGGTGGA
exons 2,3 ATGAACAAATGACTGGCCGA TAAGTTCTTGCCCAGCTCTTG
exon 4 AAGCCCCCTCTTGACCTCT CCTGGCCCAGTGAATAGTAGA
exon 5 TTGAGGAAGGGTTTCCAAGAC CAGCGAATTAAAACAAGGGG
exons 6,7 AAAAGCAAGAGTGACCCCGAT AGATTCAGGAGAGCTGGGCT
exons 8,9 GATTCACAACATGCAGCCACA AATAAAGGCACTTGGCTCAGA
exon 10 GAGAATCAAACACAAGGCATG AAGGCACTGAGCACAATGCT
exons 11,12 TGGGCCTTAGGTTTCTTCAT ATAGTCTGTGGGCTGGTTCCT
exon 13 ATGTCAAGCCACAAGGTGAA AGATGAAGGTTGGAGAGGCTC
SNRPB exon 1 AGCAGCTCTCAGTACGGATTT CGCCAAGGTCCTGGTCTTT
exon 2 GTGGCATGGGAGAATTCCTA AGCGTTCAATGTCCCCATTT
exon 3 GGGCTATCTTGGGAAAGTTTG CCTCTTGCAGGGTAACCTCTT
exon 4 AATGGTGTTGGCACACATGGA CTTTTCACTTGCTTCTAGGGC
exons 5,6 (SNORD119 ) TGGTGCTGAGAGTTGTAGCAT GCCCCAAGAATATAGCTCAAG
exon 7 ACATAGGAACCCAGTCAGCCT GGGAAGAAGGTAAGATCAGGG
ZNF343 exons 3,4 GATGGAGACTCCGTGTTTGTT TCAAGAAAGCCTAATGCTTCA
exon 5 TGTCAAGGGCCTAGAATGTGT TAGAAAGTAAGCCCCATGGAG
exon 6 TTTGCAAGGGGGAGAGATG TTATGGCTGCAACTCAATGG
exon 7-1 GGCATGGCAGTAAAACATTC TCACAAAAGCTTCGTCCACA
exon 7-2 GTGTGGGCAAAGCTTTAGAA TACACAGGGTCTACTCCCCAT
TMC2 exons 1,2 AATCTCAAACCAAGAAGCCCC TCCCATGTTAAACACCTTGCC
exon 3 TTTGGGGTGTCCTGTTCTGA TTCTGGGATGAAGAACCCAC
exon 4 TAGAATTTTGGCCTCCGCT AGTCCTCCGAGTCTTCCATG
exon 6 TTCTGCCTACCATGCCTGTTA AATTGGCAGGATACGATTGG
exon 7 CGTTGGGGAAGTAAAGGTTTG TGGCCTGACAAGTTCAAAAC
exon 8 TTCACTTTCTGACTGTGGGCA CAATTACTTTTGCACCAGCC
exon 10 AGCTGAGACTGTGCTATTGCA TGCAGAGACATGGTTTGCA
exon 11 AGGAGGTGAAGGGAAGAACAA ATGGCCTGGTTCATGTCTTT
exon 12 TGTCCTGGCTATCCTCAAAGC ACCAGCCACGAACATTCTTA
exon 13 ACCACGTCTGACACATGGTGA GTTGTAAAAGCCAGTTCCCAA
exon 14 CATGTTGATGCCTTTGCCA AACAATGGTCATCTTTGGGTC
exon 15 TGAAAGCCTGAGAAGGGAAT CAAAGAGATTTGGAGTTCCCA
exon 16 TCGCCTCTCTTCACACACAA AGGAGCTCAGCAGACTTGTTT
exon 17 TGCAAGGCCTGAAAGATAGA CAGAAACTGTCCTGCTTCTCA
exon 18 ATGGTTCTGGCTTGATGATCG ATTAGTTGGGCATTGTGGTG
exon 20 TCTGGTTCTTCCAGGAAAGCA CCATGCATTTTCCTTTCCCT
exon 21 CAGGACCTTCTCCACATTGA TGCATGCTGTTGAATCTCACA
exon 22 AATCGCTTGAACCCAGGA ATTCACCTGCCCAACTTCAT
exon 23 AGTGCAATCCGACAGCTCTCA TCAAGCGATCCACCCACCTT
NOP56 exons 1,2 (MIR1292 ) TTCCCAAGTCGTTTCGCC ATCTAGAGCTTTCCAGGCCC
exons 3,4 TGAAGGAAGTGGAGGAGATCA CCTTGAGCTCTGTGAAGACAA
exons 6,7 TGATGGGGAGGGATCTAGGTA AACACAGCCTGTGGTAAGCA
exon 9-1 TGGATCTTTGTCCCATTTCC TGGTCAGCCATCACCGTGA
exon 9-2 (SNORD86 , SNORD56 ) ATGCTGGCAGCCTCACCAA CAGACAGTTCATCACCTCCAA
exon 9-3 (SNORD57 ) GGAGAAGCTTCGAGAACAAGT AAAAAACACCCACCATGCTG
exon 9-4 TGGGCTGAGGTAATTTCTCAT ACTGAGGCTGTCATTGCTGC
SNORD110 exon 1 TCTGCTTTCTGTTCGATTGG TCAGGGGAAAGAACACAGTTC
SNORA51 exon 1 CCACCCATAATACTGGAGCCT TGCAAAGAGCCACAGTCACT
IDH3B exons 1,2 AAAAGGAGAAACAGGCGTGA ACGGATCCTGGGAGTAGAGAA
exons 3,4 AATCTGGCTGGGGTCTCTCT TGGTTGCCCTGGAGTTAATA
exons 5,6 TTACTGATGTGGGAATGGGA TCACAAGCACATCAAACTGGT
exons 7,8,9 CCCCAAAATCAAATTTGAGAC AGATGAAGAACAGCCCTGAGA
exon 12 ATCCTGGCTCCTCCTTCCATT AAGAGGCGGTTGGCAAGA
EBF4 exon 1,2 GGAAATGCGGGAGTACAGTCA TCAGAAATCTACCGGGGCA
exon 3 TCCAACATTCAAGGCCTATCA TTGAGTCTTCAGGGGAGTCAG
exon 4 TTTTTGCCCAAACTCTTGGC GGACAAGATGGGAGGATGCT
exon 5,6 AAGTTGGGGTTAGGAGAAGGG TAGAACAGAGGGCAAAAGCCA
exon 7 TAGGCTTGGGAGATGCCA TAAACAGGCCAGGCTAATGG
exon 8 ACATCAGCACCCTCAGCTCA TCCAGAAAGTTGGCCACCT
exon 9 CCATGATGGGAATATGGGAT ACAAGTTGAGAAGGAGCTGCC
exon 10,11,12 TTTTTGTAGCGCCTGGGGA AATGTTCAGGAGGTGAGATGG
exon 13,14 GAGTTTTCCGGGGGACTTG TGCTGAAGGCGTTGATGC
exon 15,16 AGTAACCAGGTATGGCGCCTC CGGCAAAGAAGGCTAAAAGT
exon 17 AACAAAGTACCCCAGGGTGCA AAGAGCAGGTTAGCCAGCAT
exon 18 AAAGTGCTATATCCCCTGCC AGGCTTGAGCACAGGATGAA
CPXM1 exon 1 TCCTGTTGGTCGACTTGATG TGTGTGAATGTGTGTGAGTGC
exon 2 TGCTGTGGGCTCACATGTC TAAGGTTGCTCCTGCGCTA
exon 3 AACCTTAGGCTCAGCTTCCCA GACACAGGACATGGTGGTCA
exon 4,5 ATGGTCTCAGGGTAGGGAAGG AAGGCAAGAAGTGATGTGGA
exon 6 TCTAGCTGAGCCCACTAGGGT AAAGGGTGTGTCCACAGTGAA
exon 7 AGTCAGGCCAGGGTTGGTT TCGATGCTCTGGTTGTTCCA
exon 8,9 ACTCTGTCCTTCTGCCCTGGT GAACAGACGCCAGCACTGTA
exon 10 TGAAGTGTCCCTCAGAGAAGG CCTGTGTGCTTCCAAGACAAT
exon 11,12 TTCATGTTCCATGGAGCTCA TGGTACCTGTAGCAGAAGCTG
C20orf141 exon 1 CACCAGCTGCTTATGAGGTCA TGCTGCCCACTTACCTATGGA
exon 2 TGGCAGGTGGGCATTGTA TTGGGCTCCCTGGCTAGTAT
FAM113A exon 2 TCACCTCCTCCCTTTAGCATT ACTGGACGGAACAGACCAGAA
exon 3 TCTGTTCCGTCCAGTAGGTTT TTGAGCAGCGACCATATCTGT
exon 4-1 ATCAACTCCTGCCTCTGGGAT TTTCCACTCCTCACACCCAT
exon 4-2 CGGAGCAATATTCTTGTCCA TCAAAGGCCTAAGCCATCAA
exon 4-3 TGTAACACTTGGTAGCCAGGA TTGTTTTAGGTAGGCTTGGGA
exon 4-4 AAGGAACACACTTTGGGCTTG TCCAGGTGAGCTTCTCTGTTT
exon 4-5 TCCTTGTGCCCCTAGCACT GGAGGGCACATTCAATGATT
VPS16 exon 1 AAGTGAGGCTGCCCACAGT TGTGCGCTAAGTGGCAGA
exon 2,3,4 AGCCTTGTGGAAGACAAATGGA CGGAACCAAACTCAGTGTGAAA
exon 5,6,7,8 GACACTTCAGCATGGGCAATGTA CGAATCAAGGAACTGATTGTCC
exon 9,10,11 GCTGTCCCGAGACAAAGGATTA TGGAGGACATAGTGTCTCTTCA
exon 12 TGGGTTACTATTGGGAGGAGTTCT TGGAGAATAAGCCCCGCTT
exon 13,14 TATAGCCAGTATCCCTGTGCACG TGTTGGGATTACAGGCATGA
exon 15,16,17,18 TAAGGGCTTGCAGGAGTGGA AACACGAAGGCCTAGATTCCT
exon 19,20,21 ATCCCTCTAGGACATCAGAGTGG AGCTGAACAGGAGCATGAA
exon 22,23 GGGGTTGGGGGATTATATGTACT GGAACACATGGAGTTTTGCTGT
PTPRA exons 1,2,3,4 ATCCAGATGTTTGTGACACCC ACAGTGAGGACCAGATGGAGT
exons 5,6,7 AGCCATCCCTCTAGGACATCA TGCCTGCCCACAAATGTGTAT
exons 8,9 TGGTTTAGGTGATTTCTGCCC GCTTTCCTTGGTAACTGTGGA
exon 12 TGCCTGGCTACTTTTTGTGGA ATGCCACCACATCTGGCTAAT
exon 15 TGAGGAAGCATGCATATCAGG CAATGCTGAGCATTCAATTCC
exon 16 TGTTGAGGGGGATTGGTCT CTTCACTCATGCTAACCCAAA
exon 17 CCAGACCACTGTCCAAAGTTT AGGGGAAAAACAACACAAAGA
exon 20-1 CACCTCAATAGCCCTGGCAT TGGGCTTGGACAGATGGAA
exon 20-2 TTCCAGTGTGCCAAGGGTAA TGGAGGCTAAACGGGGTTCTA
exon 21 TCTTACAGGCTTGGTCCATGA GGTGAGGCAAATCTCACTTCA
exon 24 TAAGGAGCTTGTGGCTGTTTC ACCTTGGCCTTCCAAAGTTCT
exon 25 TGGCATCTTTATACAAGCGTG ACATGGGAAACCATAGGGAA
exon 27 CCTGGCCTGGATTTCTTATT CAAGGACAGAGGGCCTTATTA
exon 28 CCTGGCACATACATGGTAGAA TCTAGGCACACACCTGAGGTT
exon 29 AAGAGGTCAAAGGGCCTTCT TTTCCACAGTGCTTGGTCAT
exon 30 TTTTAGTTCTGACCCTGCCA TAATCTTGGAGGACTGCCCTA
exon 31 TTCTAGCTGGAGGTCAGGATT TTGGGGCTAGGGTTACAGATT
exon 32 TGCATTTCAAGTCCCACTTCA AGTGATTCCAACGTGCAGGAT
exons 33,34 CCAGCTGAACATATGGGAACA AGTGGGTGGGTGAGTATCAAT
exon 35 CAGAAAGCAACCAGCTTGTCA TTGGGAGAAGCTAATGACTGC
exons 36,37 ACGAAGCGTATCAGCGTAAGA TAGCATCCAATCCTGTCTTGG
exon 38 TGAGTCCCTCCACAGCACAT TATGCTCCCATTGCTGCCAT
exon 39 CAGAGCTCAGGTGAAAGTTCA TTTCTCGGCTGAGGATTTCA
GNRH2 exon 2, 3 GCAGAGAGGGAAGGGCATAA TGAGAAATGGCTGGGGGT
exon 4 TAGCTGGATCCTCAGGCTTCT GGGGCCATCCCTTAGTTACT
MRPS26 exon 1 TTCGGTTCCAGAGGCCACA TTCCTCTGCACCTCGGACA
exon 2, 3 TTACCAGCACTACCGCCAGA TTTGCGCCTGACTGGCACT
exon 4 AGAGCAGGAGCTGCTTTCTCA TGCGTTTGGAAGTTTCTGAC
OXT exon 1 AATGAAGAGGAAAGCCCGTA TCAAAATCCGCTCAGCTCCT
exon 2, 3 GGAGCTGAGCGGATTTTGA AGAACAGCACCCGCTCTGT
AVP exon 1 TGTCCCCAGATGCCTGAAT ATGCCATGCCTCCCTCTT
exon 2, 3 AAACCAAGGTGCCGAGCAGAT TCCCACCTCTCTCCCTTTC
UBOX5 exon 4 AAGGAAAGTCAGTGTGGACCG TGATTCTAGAGGTGAGCCTGC
exon 5-1 CCTGATCTGGGACAATTCAGT TGCGGTTACACTTCTCCAGT
exon 5-2 AGAAGCTGGCCGAGATCATT TCTGAAGACAAAGCTGAGGGG
exon 6 TACCTCCCGGTGTTCTGTCAT AGGGTGGGTGTTGGAACTGA
exon 7 CCACTCCCCTACCTGATCAGA AGCGCAGAAGCAATGTGCTAT
FASTKD5 exon 2-1 TCATTTGTGATCCCTGGCTC ATGCTGCTCTGCAGGCAAA
exon 2-2 CCGTGTTCACAGCTATAATGC ATGTGATCCACGTGAGTGAAA
exon 2-3 AGGTTGGTACCATCTGTTTGG ATACCACAGCAATTCAGACCC
exon 2-4 AGGGTTTGTCAGGTTAGCTCA AACTCTACCACACGGTAGCCA
exon 2-5 TAGCAGATAAATCAGGGGCCA TAGCTCTAACCTGCCTTGGAT
ProSAPiP1  exon 1 ATTCCTTCACCTTGGATGCCT CACAACCCAACCTCCAAGAA
exon 2-1 GGGAACCTCAGGGTGGAAAT AGCTCCTGGATGAGTGCACTG
exon 2-2 TCCAGCAAGAGTGGGTCGT ATTGATTTTTGTCCCCCCTG
exon 3 TTGAGTCCAGGCAGGGAAT AGGGAGGAACCTGGTCACA
DDRKG1 exon 1 GGACATACCGTCTGCTATAATTTCC TTGGAGTCGAGAGAAAGGGGTA
exon 2 CCTTGCCAGTCAGACTGAGA AACAAATGCCAGGTCCCAA
exons 3,4 AGTGACATTTGCAGGTGGGT AGGGACCAAATAAACCAGGA
exons 5,6 TTGGGGGAATGGAGAAATG GGGTTGGAGGGAGAGAAACT
exons 7,8 TACAGTGTTTTTCCAGCCACC TCCTCCTTGTAACTGCATCCA
exon 9 TGATTCGACTCTCCTAGCAGG TTATCTAGGTCTTGGGGGCA
ITPA exon 1 AGAGAAGAGCGAAAGCAGGG TTCTTGCGCCCCAGCTTTT
exon 2, 3 GTAAGCTTTAGGAGATGGGCA CGGTCCTAGAAAGCTCAACAA
exon 4 CCAAAGTTAAGAGATTGGCCG AAAGAAAGGCATGCTTCTCC
exon 5 TGCTGGGATTATAGGCGGGA TACAGGGTACGAGCTGCAGGT
exon 6 CCGCTACCCCAATTGAGA TGAAAAGCTGGAAAGGCTGA
exon 7 AGCAAACATTTGCAGGTGCT AGATTCCTAGTGTCCACCCCA
exon 8 ACTCCCCTTTCCTTGGGGT TCCACTTGCCAGAGTTTCTCA
SLC4A11 exon 1 AGTCGAACGTTTTCCCAGAAG CAGAGCCCTAATGAAACCA
exon 2,3 TTTTGGACCAACGGCTCTG AGATAGGCGAGCAAAGCCA
exon 4,5 TTCCTCGCCTATGGGATG TCCTGGAGGCATGGGAAGA
exon 6,7 TGATGGCTTCCCTGAGAAT TCTTCTCCCAAGTTGGTTGG
exon 8 TTTTCCCTCCCTAGCAGAGGT CAACATGTTTCTGACACACCCA
exon 9,10,11 AAAACCTGCTGCCAGTTCATG AATGGCTGCCCAGAGAAGA
exon 12 ATCGCTTTCGGGTCTCTCAA TTGGGGCAGCAATATGGT
exon 13 ACCATATTGCTGCCCCAA TTGATCACGGGCACACACT
exon 14,15,16 TTGATCACGGGCACACACT TTCACCAGCCTGCAGCAGA
exon 17,18 TTGGTGAATGCACCGGAGAA ACCCTCCGGATGTAGTGTGT
exon 19,20 CTCTATGGCCTCTTCCTCTACAT AGTCACCCACACACCTACACCT
C20orf194 exon 2 TTAAGAAGTGGGGTCCCTGT TGAGCCGTTCAGCAAAGAA
exon 3 ATCCCCAGCAAAGTCATTCCT ACAAATTTCGGGGGAACAAG
exon 4 GTTTCTGGCACAAAACTGGT ACTGGGGCTTTGGACTATTT
exon 5 TTTGGTTTACAAGGCACAGTG TCCTTTTGTCTCCACAGGCATA
exon 6 CTTTGGAAACACCTCCTTGGGT TTGCACAGAAAAGTCCCCAT
exon 7 TTTTGCTAGGTGAGGCCCT TAACTTGCTCCATGCCCTTGT
exon 9 TCTGTATGTGCATGTGTGTATGT TGACCGAAGCAAACTAAAATATCC
exon 10 GAGATTCATCCATAGGAGTAGCA GGGGGGAACTACTTTATGGTAT
exon 11 CACTCTCCTGAAGCATGTGTGTA GCAGAGAAACAGACACATTTACAG
exon 12 CTAGCTTGAGTTTAGTTATGTCCC GGGTTAAATCAACACACTAACTGG
exon 13 CCATCCTACATGACAGAGTAAGAC ATCCAGAAGTAATCAGAGAGGGAG
exon 14 TGGGCGACAAAGCTAAACTG TTATGTTGCCCAGGCTGGT
exon 15 GCCCAGGCATGTGACTTTT TGGTGTCAAAGAGGCCCAA
exon 17 TCATGCCTACCAAGTAGTCACAT TTTGGCTTCTAAGTGAAGGCTG
exon 18,19 AAGGATGACACACACCTCACTGT TGGGATAGGACTGAGAGAAGATCA
exon 20 AAAGTCACCTCCCAGTTCAAAGA AGTGCAGTGCTGTGATCATCA
exon 21 AGCTCCTGAGAAGGGCATTT AACAGCTAGTTCAGGACCTGACAT
exon 22 ACATGGACATGGTGGAAGGA AGGGGAGGAATGCAAATAGGAA
exon 23 ATACATTGGGCATATCTGAGCCT TCATCTACAAAGTGGGTGGGT
exon 24 CACAGGGCTCAGCATACAAATC TGTGCTGGTTCCTGACATACTG
exon 25 AGCACATCTATACTGAACCACAG ATTAGAAGCAGTCACCCCACA
exon 26 TCAGGCCTCTATTTTTGAAGCA GCAAGTTGGCAGCATTGAAA
exon 27,28 GTGTTTTGGAAGAGTTGACTCTG AAGGAAGTGGAGAGTCCTGTAA
exon 29 TGGCCTAAGGTCACAGAGTTAGT TACAGGAAGTGCTCAGAAGAGCAT
exon 30 CCAAGATGGCTTTCTCCTGAATG CTGCTCATGCATGTAGAGTCTGTT
exon 31 AGATTGCGGGCTCTTCCTTTT TCCAAAGGGGTCTATTGAGGA
exon 32 CATGGCTATCCTTAGTGCTCAGT GCTCTTGGAAGAAATGTGCCTA
exon 33 TATTGGGGTGTAAGGGTTGTCT TGGCTCAAAAACTGACTTCTCC
exon 34 ATTACCTGGGTATGATGGCACA TTGCTGCCTACAGGATGATT
exon 35,36 GACGGGGTTTCACCTTGTTAG TTTCTGAGAGTCTGAGCAGCAT
exon 37 ACCTACTCCATCCTTTCTAAGCTG TCTCTCAAAGTGTCCCTGCAA
exon 38 TTATATCCAGGCCATAGCGCA AATTCTGTACGCAGCTTCCCT
exon 39 AGGCAGGGCTTGAGGTTT TTTGCCCCTGTGCATTCCT
exon 40 ACAAAGAGTCCATCAGGTTCCCT ACAACATGCACTCAAGCCA  
Supplemental Table 2. Variants identified by candidate gene sequencing 
Start End NT_011387.8 Chr （V37.1)
PDYN
NM_024411.2
1959402 1974702 No variation No variation No variation No variation No variation
2022732 2082732 rs6112857 Arg69Gly CC GG GC
2022767 2082767 rs6106228 Gln80Gln GG AG AA
exon 3 2037688 2097688 rs1891227 Ala423Ala TT CT CC
intron 12 2255929 2315929 rs2076406 IVS12+10 GG AA AA
exon 7 2237790 2297790 rs214814 Ser249Asn GG GG GA
5' near gene 2301505 2361505 rs9680025 5' near gene AA AG GG AG AG GG
intron 1 2301684 2361684 rs2422753 IVS1+63 CC CT CC CT CC CC
exon 2 2315262 2375262 rs2076405 M58V TT TC CC CC TC CC
intron 2 2315440 2375440 rs7266902 IVS2+169 GG GT TT GT GT TT
exon 6 2320323 2380323 rs6114033 Lys263Lys GG GG GA GA GG GG
2320396 2380396 rs2076404 IVS6+12 CC TT CT CT CT CT
2320628 2380628 - IVS6+242 CC CC CC CT CC CC
2320629 2380629 - IVS6+243 GG GA GG GG GG GG
2324151 2384151 rs6137891 IVS8+5 GG GA GA GA GA GA
2338017 2398017 rs2295077 Lys492Lys CC CT CT CT TT CT
2351368 2411368 rs2076648 IVS12+121 CC CC CC CC CC CT
2351737 2411737 rs11470465 IVS12+64 GA/GA -/GA -/GA -/GA -/GA GA/GA
2353125 2413125 rs2076653 IVS12–11 GG GA GA GA GA GG
2353126 2413126 rs6036467 IVS12–10 CC TT TT TT TT TT
2353320 2413320 rs2076652 3'-UTR AA AG AG AG AG GG
2353472 2413472 rs45610835 3'-UTR TT TT TT TT TT TG
5' near gene 2391504 2451504 rs6049290 5' near gene CC CC TC
5' near gene 2391503 2451503 rs4815262 5' near gene AA AA GA
exon 1 2391451 2451451 rs6049288 5'-UTR GG GG TG
intron 3 2384665 2444665 rs73606142 IVS3–120 TT CT TT
SNORD119
 NR_003684.1
2443598 2443693 No variation No variation
intron 3 2414176 2474176 - IVS3–11 TT TT TC
intron 4 2413587 2473587 rs41308639 IVS4–22 AA AT AT
exon 7 2403921 2463912 - Leu565Leu TT TT TA
exon 3 2539387 2479387 rs6050063 Arg123Lys AA AG AG
intron 3 2539568 2479568 rs4815320 IVS3+148 TT TA TA
2542669 2482669 rs7270277 IVS4+13 CC CT CC
2542747 2482747 rs4815323 IVS4+91 GG GT GG
2552926 2492926 rs1883980 IVS6+11 AA AG GG
2559778 2499778 rs6083735 IVS6–14 GG GC CC
intron 9 2572816 2512816 rs6050433 IVS9–139 TT TG GG
intron 13 2591005 2531009 rs1883978 IVS13–59 TT GG GG
exon 14 2591232 2531232 rs6050576 Asp527Asp CC TT TT
intron 15 2593006 2533006 rs1015159 IVS15+20 AA AG GG
2593863 2533869 rs6515646 Ser589Ser TT TC TC
2594254 2534254 rs6115181 non-coding AA AG AG
intron 16 2596762 2536762 rs6050622 IVS16–21 GG GA GA
intron 17 2596969 2536969 rs4621228 IVS17+118 TT TT TA
2597978 2537978 rs4815428 non-coding GG GG GA
2598019 2538019 rs6083566 non-coding CC CC CT
2598405 2538405 rs13040075 non-coding GG GA GA
intron 20 2616556 2556556 rs910271 IVS20–26 TT TC CC
2616679 2556679 rs2422808 IVS21+29 CC CG GG
2616776 2556776 rs13038659 IVS21+126 TT TG TG
2618094 2558094 rs6037181 IVS21–26 GG GG AA
exon 22 2618140 2558140 rs6083915 Ser802Ser TT TT CC
intron 22 2618308 2558308 rs6050771 IVS22+71 CC CC TT
exon 23 2561998 2621998 rs6050798 3'-UTR TT TT CT
exon 1 2573296 2633296 rs6138678 5`-UTR GG GG CG GG GG GG
intron 1 2573397 2633397 rs68063608 IVS1–25 g.263397_263403[5] g.263397_263403[6]+(2300) g.263397_263403[8]+(2200) g.263397_263403[6]+(2200) g.263397_263403[6]+(2000) g.263397_263403[8]+(1700) 
exon 9 2577071 2637071 rs8958 Thr345Thr TT CT TT CT CT TT
MIR1292
 NR_031699.1
2633423 2633488 No variation No variation No variation No variation No variation
SNORD110
 NR_003078.1
2634858 2634932 No variation No variation
SNORA51
 NR_002981.1
2635713 2635844 No variation No variation
SNORD86
 NR_004399.1
2636743 2636828 No variation No variation
SNORD56
 NR_002739.1
2637270 2637340 No variation No variation
SNORD57
 NR_002738.1
2637585 2637656 No variation No variation
IDH3B
 NM_174856.1
2639041 2644843 intron 2 2584407 2644407 rs2073193 IVS2–3 GG CC CC
intron 1 2614174 2674174 rs55820831 IVS1-133 AA AG AG
intron 2 2617329 2677329 rs874688 IVS2-11 TT TC CC
exon 3 2617566 2677566 rs2325900 non-coding TT TT TC
intron 3 2618202:2618203 2678202:2678203 rs11474226 IVS3+5:8 -/- -/AAAG AAAG/AAAG
intron 12 2670870 2730870 rs6138883 IVS12+236 CC GC CC
intron15 2672934 2732934 rs60014511 IVS15+49 GG AG GG
exon17 2676104 2736104 rs13042767 non-coding GG CG GG
CPXM1
NM_019609.4
2774715 2781292 intron 6 2717828 2777828 rs742707 IVS6+10 GG AG GG
C20orf141
NM_080739.2
2795657 2735657 exon 1 2736007 2796007 rs12625619 Leu59Leu GG AG AA
2758801 2818801 rs751899 non-coding TT TC CC
2758480 2818480 rs2325970 non-coding AA AG GG
2757100 2817100 rs78139021 non-coding TT TG TT





















































exon 3 2780773 2840773 rs3818605 Ser72Ser CC CT CT
intron 10 2782685 2842685 rs6051449 IVS10-15 AA AC CC
intron 11 2783053 2843053 rs632080 IVS11-49 AA AG GG
intron 16 2784983 2844983 - IVS16-28 AA AC AC
intron 17 2785130 2845130 rs730819 IVS17+22 GG GA AA
intron 3 2785130 2845130 rs730819 IVS3+22 GG AG AA
intron 26 2936423 2996423 rs1178015 IVS26–73 TT AA AA
exon 27 2936497 2996497 rs1178016 Gly303Gly CC TT TT
intron 27 2936589 2996589 rs1178017 IVS27+58 GG TT TT
2942889 3002889 rs544090 IVS31+23 TT GG GG
2943027 3003027 rs2277756 IVS31+161 TT CT CT
intron 37 2957674 3017674 rs561843 IVS31–126 TT GG GG
exon 2 2965107 3025107 rs6051545 Ala16Val CC CT CT





rs71195814 frameshift -/- -/CCCCG -/CCCCG
2966415 3026415 rs8184100 3'-UTR CC CT CT
MRPS26
NM_030811.3
3026675 3028896 inton 2 2967220 3027220 rs2277757 IVS3-40 GG GA GA
OXT
NM_000915.2
3052266 3053162 No variation No variation
AVP
NM_000490.4
3063202 3065370 No variation No variation
UBOX5
NM_014948.2
3088219 3140540 exon 7 3030848 3090848 rs708973 Arg510Arg TT TT TG
FASTKD5
NM_021826.4
3127165 3140532 exon 2 3068403 3128403 rs3746698 Gly438Gly AA AG AA
exon 1 3087468 3147468 rs17853865 Asn114Asn GG GG GA
intron 1 3087024 3147024 rs7260750 IVS1-13 AA AA AG
intron 1 3124134 3184134 rs2295553 IVS1–73 CC TC CC
intron 4 3116072 3176072 rs7263489 IVS4–73 CC AC CC
intron 5 3115556 3175556 rs2295549 IVS5–42 CC GC CC
intron 7 3112246 3172246 rs2295547 IVS7–16 TT GT TT
5' near gene 3130039 3190039 rs45620433 5' near gene CC CG CC
exon 3 3133978 3193978 rs8362 Gln46Gln GG GA GG
intron 5 3144176 3204176 rs75609817 IVS5-17 GG GA AA
exon 8 3144084 3204084 rs9101 Glu187Glu GG GA GG
5' near gene 3159894 3219894 rs6107260 5' near gene TT TC CC
exon 1 3159698 3219698 - 5'-UTR GG GG GC
exon 1 3159692 3219692 rs6084314 5'-UTR GG GA AA
exon 2 3158634 3218634 rs3810562 Pro26Arg CC CG GG
exon 3 3158355 3218355 rs3827076 non-coding GG GC CC
intron 3 3155548 3215548 rs3803957 IVS3-8 GG GT GT
intron 5 3155088 3215088 rs6133022 IVS5+126 GG GA AA
exon 6 3154819 3214819 rs3827075 Arg145Arg AA AC CC
intron 8 3154126 3214126 rs3803955 IVS8+34 GG GA GA
intron 10 3151719 3211719 rs3803953 IVS10-15 AA AC AC
intron 17 3149371 3209371 rs2281575 IVS17-18 CC CT CT
intron 17 3149357 3209357 rs10048856 IVS17-4 GG GG GA
exon 4 3302033 3362033 rs6051818 Val92Val AA AG AG
intron 4 3302009 3362009 rs2008730 IVS4+17 AA AA AG
intron 6 3295567 3355567 rs2208030 IVS6+110 AA AG AG
exon 11 3264373 3324373 - Phe265Leu CC CG CC
exon 12 3261244 3321244 rs80335486 Thr296Thr TT CT CT
intron 19 3239054 3299054 rs6139071 IVS19-7 AA AG AG
intron 22 3236279 3296279 rs2236115 IVS22+103 GG AG AG
intron 23 3236428 3296428 - IVS23-99 -/- T /- T /-
exon 24 3225140 3285140 rs2422864 Arg577Gly TT CC CC
intron 25 3217602 3277602 rs2236104 IVS25-6 CC CA CA
exon 27 3215239 3275239 rs2281504 Ser685Ser GG AG GG
intron 34 3180723 3240723 rs6051685 IVS34-49 CC CG CG
intron 37 3176554 3236554 rs117680746 IVS37+98 GG AG AG
exon 38 3175916 3235916 rs2281496 Lys1092Lys TT CT TT




























Supplemental Table 3.  Primers used for repeat-primed PCR, Southern blotting, and RT-PCR. 
For  repeat-primed PCR
Primer name Primer sequence
Forward primer TTTCGGCCTGCGTTCGGG
First reverse primer TACGCATCCCAGTTTGAGACGCAGGCCCAGGCCCAGGCCCAGGCC
Second reverse primer TACGCATCCCAGTTTGAGACG
For probes for Southern blot analysis.
Primer name Primer sequence
Forward primer  TTTAAGAGCTTCCAAGGCTGA
Reverse primer  AGTGCCCACAAGGAAACCGTTA
For quantitation of mouse NOP56 cDNA
Primer name Primer sequence
mouse NOP56 F GTTGGCGCTGAAGGAAGTGG
mouse NOP56 R CTTTGGCACGAGAGTAGCTG
For quantitation of human NOP56 cDNA
Primer name Primer sequence
human NOP56 cex4F  TTGCCTTGGAAAATGCCAAC
human NOP56 cex6R  TGTATTGCGGCACCAATCTT
For investigation of human NOP56 cDNA splicing variants
Primer name Primer sequence
human NOP56 cex1F TAGCCGCATTGCGAGCCGAA
human NOP56 cex4R GTTGCCTTGGAAAATGCCAA  
  
AJHG Conflict of Interest Form 
 
Please complete this form electronically and upload the file with your final 
submission. 
 
AJHG requires all authors to disclose any financial interest that might be construed 
to influence the results or interpretation of their manuscript.  
 
As a guideline, any affiliation associated with a payment or financial benefit 
exceeding $10,000 p.a. or 5% ownership of a company or research funding by a 
company with related interests would constitute a financial interest that must be 
declared. This policy applies to all submitted research manuscripts and review 
material.  
 
Examples of statement language include: AUTHOR is an employee and shareholder 
of COMPANY; AUTHOR is a founder of COMPANY and a member of its scientific 
advisory board. This work was supported in part by a grant from COMPANY. 
 
Please disclose any such interest below on behalf of all authors of this manuscript.  
 
Please check one of the following: 
 None of the authors of this manuscript have a financial interest related to this 
work. 
 Please print the following Disclosure Statement in the Acknowledgments section: 
      
 
Please provide the following information: 
 Please check this box to indicate that you have asked every author of this work to 
declare any conflicts of interest. Your answers on this form are on behalf of every 
author of this work. 
Manuscript #: AJHG-D-11-00147 
Article Title: Expansion of Intronic GGCCTG Hexanucleotide Repeat in NOP56 
Causes a Type of Spinocerebellar Ataxia (SCA36) Accompanied by Motor Neuron 
Involvement 
Author List: Hatasu Kobayashi, Koji Abe, Tohru Matsuura, Yoshio Ikeda, Toshiaki 
Hitomi, Yuji Akechi, Toshiyuki Habu, Liu Wanyang, Hiroko Okuda and Akio Koizumi 
Your Name: Akio Koizumi 
Date: 2011/5/15 
COI Form
